Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Gyre Therapeutics, Inc.'s quarterly P/E stands at 8.1x, down 87.4% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 64.5% YoY to 24.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 164.80 | 8.11 | 835.23 | 448.84 | — | 64.24 | 88.24 | 59.54 | — | 34.68 | 16.45 | 10.27 | — |
| — | -87.4% | +846.5% | +653.9% | — | +85.2% | +436.5% | +479.9% | — | — | -81.3% | -66.8% | — | |
| P/S Ratio | 6.72 | 6.27 | 7.05 | 8.92 | 11.10 | 12.62 | 12.34 | 16.50 | 18.12 | 4.30 | 3.14 | 2.21 | 4.44 |
| — | -50.4% | -42.9% | -45.9% | -38.7% | +193.4% | +293.3% | +645.3% | +308.3% | +9.6% | — | -98.9% | -89.9% | |
| P/B Ratio | 8.57 | 5.58 | 5.83 | 7.55 | 12.58 | 13.07 | 13.33 | 20.20 | 141.07 | 156.81 | 3.77 | 2.29 | 7.00 |
| — | -57.3% | -56.3% | -62.6% | -91.1% | -91.7% | +253.6% | +781.0% | +1915.2% | +2373.2% | -82.3% | -90.0% | -32.9% | |
| P/FCF | — | 47.97 | 104.32 | — | — | 327.34 | — | 168.99 | 475.30 | 24.59 | 44.77 | 6.36 | 114.79 |
| — | -85.3% | — | — | — | +1231.0% | — | +2555.9% | +314.1% | — | — | — | — | |
| EV / EBITDA | 39.49 | 23.99 | 63.99 | 68.89 | 287.34 | 67.61 | 87.89 | 51.96 | — | 10.59 | 16.37 | 7.01 | 24.88 |
| — | -64.5% | -27.2% | +32.6% | — | +538.4% | +436.9% | +640.8% | — | -52.7% | — | — | — | |
| EV / EBIT | 43.37 | 23.82 | 82.85 | 85.10 | 462.87 | 75.19 | 94.30 | 54.64 | — | 10.76 | 17.42 | 7.32 | — |
| — | -68.3% | -12.1% | +55.8% | — | +598.9% | +441.4% | +646.9% | — | — | +123.9% | -60.6% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Gyre Therapeutics, Inc.'s operating margin was 22.7% in Q3 2025, up 14.5 pp QoQ and up 6.0 pp YoY. The trailing four-quarter average of 10.8% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.3% | 94.7% | 95.7% | 95.9% | 95.8% | 96.2% | 96.9% | 96.4% | 95.4% | 96.3% | 96.3% | 95.5% | 95.2% |
| — | -1.6% | -1.3% | -0.5% | +0.4% | -0.1% | +0.6% | +1.0% | +0.2% | +1.1% | — | +19053.5% | +16694.9% | |
| Operating Margin | 15.3% | 22.7% | 8.1% | 10.3% | 2.1% | 16.6% | 12.9% | 29.7% | -337.5% | 39.8% | 17.0% | 26.7% | 16.2% |
| — | +36.4% | -37.3% | -65.3% | +100.6% | -58.3% | -23.7% | +11.1% | -2188.9% | +152.5% | — | +101.4% | +101.9% | |
| Net Margin | 11.4% | 11.8% | 1.7% | 12.2% | -0.4% | 4.4% | 14.0% | 27.7% | -372.1% | 12.4% | 6.3% | 9.0% | -12.2% |
| — | +167.8% | -88.2% | -55.9% | +99.9% | -64.5% | +121.4% | +208.0% | -2945.1% | +208.4% | — | -98.6% | +98.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.5% | 2.7% | 0.4% | 2.7% | -0.1% | 1.2% | 3.9% | 14.7% | -1156.6% | 7.9% | 1.9% | 2.7% | -4.8% |
| — | +130.9% | -90.2% | -81.8% | +100.0% | -85.1% | +102.7% | +450.6% | -23904.8% | +278.2% | -98.0% | -82.0% | +87.9% | |
| ROA | 10.0% | 2.3% | 0.3% | 2.1% | -0.1% | 0.9% | 2.9% | 6.3% | -159.7% | 6.6% | 1.7% | 2.3% | -4.1% |
| — | +153.4% | -89.2% | -66.5% | +100.0% | -86.1% | +73.5% | +174.3% | -3789.6% | +265.2% | -98.0% | -78.1% | +86.4% | |
| ROIC | 35.1% | 5.4% | 1.8% | 1.9% | 0.5% | 3.9% | 3.5% | 30.2% | — | 24.7% | 5.1% | 8.5% | 7.2% |
| — | +39.0% | -50.2% | -93.7% | — | -84.3% | -30.5% | +256.8% | — | +88.9% | — | — | +100.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Gyre Therapeutics, Inc.'s Debt/EBITDA ratio is 0.2x, down from 0.5x last quarter — comfortably within a safe range. The current ratio has improved 66.3% YoY to 6.19x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.03 | — | 0.00 | 0.01 | 0.01 |
| — | -53.5% | -48.6% | +390.5% | -44.6% | — | +331.2% | -52.6% | +245.4% | — | -72.8% | -90.7% | -85.4% | |
| Debt / EBITDA | 0.09 | 0.15 | 0.50 | 0.56 | 1.50 | 0.38 | 0.56 | 0.03 | — | — | 0.09 | 0.09 | 0.13 |
| — | -59.7% | -11.4% | +1641.8% | — | — | +523.5% | -64.2% | — | — | — | — | — | |
| Current Ratio | 3.32 | 6.19 | 5.40 | 3.60 | 3.32 | 3.72 | 3.44 | 3.22 | 2.85 | 2.88 | 3.30 | 3.67 | 4.06 |
| — | +66.3% | +57.0% | +12.0% | +16.3% | +29.4% | +4.1% | -12.2% | -29.6% | -29.0% | -82.5% | +31.7% | +11.6% | |
| Quick Ratio | 2.99 | 5.64 | 4.87 | 3.19 | 2.99 | 3.29 | 3.07 | 2.97 | 2.64 | 2.88 | 2.89 | 3.22 | 3.56 |
| — | +71.3% | +58.4% | +7.6% | +13.4% | +14.3% | +6.5% | -8.0% | -25.7% | -19.1% | -84.7% | +15.8% | -2.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | 6.43 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonGyre Therapeutics, Inc.'s current P/E is 164.8x. The average P/E over the last 3 quarters is 430.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Gyre Therapeutics, Inc.'s current operating margin is 15.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Gyre Therapeutics, Inc.'s business trajectory between earnings reports.